What is new in systemic lupus erythematosus

被引：15

作者：

Fernandez de Larrinoa, Inigo Rua-Figueroa ^{[1
]}

机构：

[1] Hosp Doctor Negrin, Serv Reumatol, Las Palmas Gran Canaria, Las Palmas, Spain

来源：

REUMATOLOGIA CLINICA | 2015年 / 11卷 / 01期

关键词：

Systemic lupus erythematosus;

D O I：

10.1016/j.reuma.2014.09.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Systemic lupus erythematosus is a heterogeneous rheumatic systemic disease with extremely varied clinical manifestations and a diverse pathogenesis, as illustrated in this review on the most relevant new knowledge related to the disease. Topics such as anemia, pathogenesis, cardiovascular risk assessment, anti phospholipid syndrome, prediction of damage and recent advances in treatment, including tolerogenic and biological agents, are discussed. Relevant contributions regarding classical therapies such ascorticosteroid and antimalarials and their optimal use, as well as the roll of vitamin D, are also referred. (C) 2014 Elsevier Espana, S.L.U. All rights reserved.

引用

页码：27 / 32

页数：6

共 31 条

[21]

Rua-Figueroa Erausquin C, 2011, REUMATOL CLIN, V7

[22] Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review [J].

Ruiz-Irastorza, G. ;

Ramos-Casals, M. ;

Brito-Zeron, P. ;

Khamashta, M. A. .

ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (01) :20-28

[23]

Silva-Fernandez L, 2014, J RHEUMATOL IN PRESS

[24] Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice [J].

Souberbielle, Jean-Claude ;

Body, Jean-Jacques ;

Lappe, Joan M. ;

Plebani, Mario ;

Shoenfeld, Yehuda ;

Wang, Thomas J. ;

Bischoff-Ferrari, Heike A. ;

Cavalier, Etienne ;

Ebeling, Peter R. ;

Fardellone, Patrice ;

Gandini, Sara ;

Gruson, Damien ;

Guerin, Alain P. ;

Heickendorff, Lene ;

Hollis, Bruce W. ;

Ish-Shalom, Sofia ;

Jean, Guillaume ;

von Landenberg, Philipp ;

Largura, Alvaro ;

Olsson, Tomas ;

Pierrot-Deseilligny, Charles ;

Pilz, Stefan ;

Tincani, Angela ;

Valcour, Andre ;

Zittermann, Armin .

AUTOIMMUNITY REVIEWS, 2010, 9 (11) :709-715

[25] Epratuzumab for Systemic Lupus Erythematosus [J].

Wallace, D. J. ;

Goldenberg, D. M. .

LUPUS, 2013, 22 (04) :400-405

[26] Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study [J].

Wallace, Daniel J. ;

Kalunian, Kenneth ;

Petri, Michelle A. ;

Strand, Vibeke ;

Houssiau, Frederic A. ;

Pike, Marilyn ;

Kilgallen, Brian ;

Bongardt, Sabine ;

Barry, Anna ;

Kelley, Lexy ;

Gordon, Caroline .

ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) :183-190

[27] Abatacept for lupus nephritis Alternative definitions of complete response support conflicting conclusions [J].

Wofsy, David ;

Hillson, Jan L. ;

Diamond, Betty .

ARTHRITIS AND RHEUMATISM, 2012, 64 (11) :3660-3665

[28] Toll-like Receptor 7-Stimulated Tumor Necrosis Factor α Causes Bone Marrow Damage in Systemic Lupus Erythematosus [J].

Zhuang, Haoyang ;

Han, Shuhong ;

Xu, Yuan ;

Li, Yi ;

Wang, Hai ;

Yang, Li-Jun ;

Reeves, Westley H. .

ARTHRITIS & RHEUMATOLOGY, 2014, 66 (01) :140-151

[29] Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial [J].

Zimmer, Robert ;

Scherbarth, Hugo R. ;

Luis Rillo, Oscar ;

Jesus Gomez-Reino, Juan ;

Muller, Sylviane .

ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (11) :1830-1835

[30]

Zonana-Nacach A, 2000, ARTHRITIS RHEUM, V43, P1801, DOI 10.1002/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO

← 1 2 3 4 →